Download PDF
Fortschr Neurol Psychiatr 2011; 79(12): 733-743
DOI: 10.1055/s-0031-1281820
Fort- und Weiterbildung

© Georg Thieme Verlag KG Stuttgart · New York

Therapiestandards in der Behandlung des Morbus Parkinson

Current Treatment Strategies for Parkinson’s DiseaseM. Südmeyer1, 2 , L. Wojtecki1, 2 , A. Schnitzler1, 2
  • 1Neurologische Klinik – Bewegungsstörungen und Neuromodulation, Medizinische Fakultät, UKD, Düsseldorf
  • 2Institut für Klinische Neurowissenschaften und Medizinische Psychologie, Medizinische Fakultät, UKD, Düsseldorf
Further Information

Publication History

Publication Date:
09 December 2011 (online)

    Permissions and Reprints

Lernziele

Der vorliegende Übersichtsartikel beschäftigt sich mit den Therapiestandards in der Behandlung des Morbus Parkinson unter Berücksichtigung der Leitlinien der Deutschen Gesellschaft für Neurologie und aktuellster Studienergebnisse. Ziel der Darstellung ist es, Kenntnisse in den 3 folgenden Bereichen zu vermitteln:

Behandlung motorischer Symptome im Früh- und Spätstadium Indikation für tiefe Hirnstimulation und Medikamentenpumpentherapien Therapie nicht motorischer Symptome

Literatur

  • 1 Oertel W H, Reichmann H. Parkinson-Syndrome: Diagnostik und Therapie. In: Diener H C, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie.. Stuttgart: Thieme; 2008: 82-112
    Google Scholar
  • 2 Braak H, Del Tredici K. Pathophysiologie des sporadischen Morbus Parkinson.  Fortschr Neurol Psychiat. 2010;  78 (Suppl 1) 2-4
    Google Scholar
  • 3 Wojtecki L, Südmeyer M, Schnitzler A. Current Treatment of Parkinson’s disease.  Dtsch Arztebl. 2007;  104 2513-2522
    Google Scholar
  • 4 LeWitt P A. Levodopa for the treatment of Parkinson’s disease.  N Engl J Med. 2008;  359 2468-2476
    Google Scholar
  • 5 Koller W C, Hutton J T, Tolosa E et al. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study.  Neurology. 1999;  53 1012-1019
    Google Scholar
  • 6 Stocchi F, Rascol O, Kieburtz K et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease – the STRIDE-PD study.  Ann Neurol. 2010;  68 18-27
    Google Scholar
  • 7 Parkinson Study Group CALM Cohort Investigators . Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease.  Arch Neurol. 2009;  66 563-570
    Google Scholar
  • 8 Schade R, Andersohn F, Suissa S et al. Dopamine agonists and the risk of cardiac-valve regurgitation.  N Engl J Med. 2007;  356 29-38
    Google Scholar
  • 9 Zanettini R, Antonini A, Gatto G et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease.  N Engl J Med. 2007;  356 39-46
    Google Scholar
  • 10 Onofrj M, Bonanni L, De Angelis M V et al. Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies.  Parkinsonism Relat Disord. 2009;  15 (Suppl 4) 85-92
    Google Scholar
  • 11 Fahn S, Shoulson I, Kieburtz K et al. Levodopa and the progression of Parkinson’s disease.  N Engl J Med. 2004;  351 2498-2508
    Google Scholar
  • 12 Schulz J B, Gerlach M, Gille G et al. Basic science in Parkinson’s disease: its impact on clinical practice.  J Neurol. 2011;  258 (Suppl 2) 299-306
    Google Scholar
  • 13 Wallace B A, Ashkan K, Heise C E et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys.  Brain. 2007;  130 2129-2145
    Google Scholar
  • 14 Rascol O. „Disease-modification“ trials in Parkinson disease: target populations, endpoints and study design.  Neurology. 2009;  72 (Suppl 2) 51-58
    Google Scholar
  • 15 Olanow C W, Rascol O, Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease.  N Engl J Med. 2009;  361 1268-1278
    Google Scholar
  • 16 Schapira A H, Albrecht S, Barone P et al. Rationale for delayed-start study of pramipexole in Parkinson’s disease: the PROUD study.  Mov Disord. 2010;  25 1627-1632
    Google Scholar
  • 17 Rascol O, Fitzer-Attas C F, Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.  Lancet Neurol. 2011;  10 415-423
    Google Scholar
  • 18 Kostic V, Przedborski S, Flaster E et al. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease.  Neurology. 1991;  41 202-205
    Google Scholar
  • 19 Entacaponeto Tolcapone Switch Study Investigators . Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease.  Mov Disord. 2007;  22 14-19
    Google Scholar
  • 20 Rascol O, Brooks D J, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.  Lancet. 2005;  365 947-954
    Google Scholar
  • 21 Wolf E, Seppi K, Katzenschlager R et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease.  Mov Disord. 2010;  25 1357-1363
    Google Scholar
  • 22 Stocchi F, Giorgi L, Hunter B et al. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease.  Mov Disord. 2011;  26 1259-1265
    Google Scholar
  • 23 Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson’s disease.  N Engl J Med. 2006;  355 896-908
    Google Scholar
  • 24 Williams A, Gill S, Varma T et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial.  Lancet Neurol. 2010;  9 581-591
    Google Scholar
  • 25 Follett K A, Weaver F M, Stern M et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease.  N Engl J Med. 2010;  362 2077-2091
    Google Scholar
  • 26 Fasano A, Romito L M, Daniele A et al. Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants.  Brain. 2010;  133 2664-2676
    Google Scholar
  • 27 Clarke C E, Worth P, Grosset D et al. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease.  Parkinsonism Relat Disord. 2009;  15 728-741
    Google Scholar
  • 28 Devos D for the French DUODOPA Study Group . Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease.  Mov Disord. 2009;  24 993-1000
    Google Scholar
  • 29 De Gaspari D, Siri C, Cilia A L et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.  J Neurol Neurosurg Psychiatry. 2006;  77 450-453
    Google Scholar
  • 30 Ebersbach G, Ebersbach A, Edler D et al. Comparing exercise in Parkinson’s disease – the Berlin LSVT®BIG study.  Mov Disord. 2010;  25 1902-1908
    Google Scholar
  • 31 Ramig L O, Sapir S, Countryman S et al. Intensive voice treatment (LSVT) for patients with Parkinson’s disease: a 2 year follow up.  J Neurol Neurosurg Psychiatry. 2001;  71 493-498
    Google Scholar
  • 32 Menza M, Dobkin R D, Marin H et al. A controlled trial of antidepressants in patients with Parkinson disease and depression.  Neurology. 2009;  72 886-892
    Google Scholar
  • 33 Timmermann L, Maier F, Eggers C et al. Demenz bei Morbus Parkinson: Sinnvolle Diagnostik und rationale Therapie.  Fortschr Neurol Psychiat. 2010;  78 513-518
    Google Scholar
  • 34 Weintraub D, Koester J, Potenza M N et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.  Arch Neurol. 2010;  67 589-595
    Google Scholar

Dr. Martin Südmeyer

Neurologische Klinik – Bewegungsstörungen und Neuromodulation, Medizinische Fakultät, UKD

Moorenstr. 5

40225 Düsseldorf

Email: martin.suedmeyer@uni-duesseldorf.de

      >